Dr. Baldassarre Stea
Claim this profileUniversity of Arizona Cancer Center-North Campus
Affiliated Hospitals
University Of Arizona Cancer Center-North Campus
Banner University Medical Center - Tucson
Clinical Trials Baldassarre Stea is currently running
Stereotactic Radiosurgery vs. HA-WBRT + Memantine
for Brain Cancer
Stereotactic radiosurgery (SRS) is a commonly used treatment for brain tumors. It is a one-day (or in some cases two day), out-patient procedure during which a high dose of radiation is delivered to small spots in the brain while excluding the surrounding normal brain. Whole brain radiation therapy with hippocampal avoidance (HA-WBRT) is when radiation therapy is given to the whole brain, while trying to decrease the amount of radiation that is delivered to the area of the hippocampus. The hippocampus is a brain structure that is important for memory. Memantine is a drug that is given to help relieve symptoms that can be caused by WBRT, including problems with memory and other mental symptoms. Health Canada, the regulatory body that oversees the use of drugs in Canada, has not approved the sale or use of memantine in combination with WBRT to treat this kind of cancer, although they have allowed its use in this study.
Recruiting
2 awards
Phase 3
Radiation Therapy vs Observation
for Meningioma
This trial studies if radiation therapy helps prevent the return of grade II meningioma after surgery. Radiation therapy uses powerful x-rays to destroy any leftover cancer cells. The goal is to see if this improves patient outcomes compared to just monitoring them. Radiation therapy has shown success in stabilizing tumor growth and reducing recurrence risk.
Recruiting
2 awards
Phase 3
12 criteria
More about Baldassarre Stea
Clinical Trial Related
2 years of experience running clinical trials · Led 6 trials as a Principal Investigator · 3 Active Clinical Trials
Treatments Baldassarre Stea has experience with
- Stereotactic Radiosurgery
- NanO2TM
- Fractionated Stereotactic Radiosurgery
- Single Fraction Stereotactic Radiosurgery
- Clinical Observation
- Radiation Therapy
Breakdown of trials Baldassarre Stea has run
Brain Tumor
Brain Metastasis
Glioblastoma
Breast Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Baldassarre Stea specialize in?
Baldassarre Stea focuses on Brain Tumor and Brain Metastasis. In particular, much of their work with Brain Tumor has involved Stage IV patients, or patients who are undergoing treatment.
Is Baldassarre Stea currently recruiting for clinical trials?
Yes, Baldassarre Stea is currently recruiting for 3 clinical trials in Tucson Arizona. If you're interested in participating, you should apply.
Are there any treatments that Baldassarre Stea has studied deeply?
Yes, Baldassarre Stea has studied treatments such as Stereotactic Radiosurgery, NanO2TM, Fractionated Stereotactic Radiosurgery.
What is the best way to schedule an appointment with Baldassarre Stea?
Apply for one of the trials that Baldassarre Stea is conducting.
What is the office address of Baldassarre Stea?
The office of Baldassarre Stea is located at: University of Arizona Cancer Center-North Campus, Tucson, Arizona 85719 United States. This is the address for their practice at the University of Arizona Cancer Center-North Campus.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.